Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.
Sep 16, 2021Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK
Sep 15, 2021Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
Sep 02, 2021Autolus Therapeutics to participate in upcoming virtual investor conferences
More events are coming soon.